For a special limited time:

         Save 30%!

 Get all 3:

           currinBiotech.com
 
            currinTechnology
  
                       and
  
              rick'sResearch

       
  
  for one low price.

                Learn more

Cell Signaling and Cancer Stem Cells - Companies in Focus

publication date: Oct 18, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

After discussing embryonic stem cells and cancer stem cells in the previous issue we highlighted 4 portfolio stocks.   Here we go into more detail on 2 of these stocks providing promising clinical trial information on their drug candidates.

The term “cancer stem cells” may seldom appear in these investments if you dig through the investor information presented by each company.  However in evaluating certain investments we looked at the mechanism of action of their drug candidates and the downstream targets impacted watching for clinical activity and the promising intersection of CSC. 



Sorry this page is available to premium members only.
If you're not a premium member why not join today?

If you are already a premium member, please login.

If your trial membership to currinBIOTECH has expired join today.

If you are a CurrinTechnology or Rick's Research member you can upgrade to currinBIOTECH at a specially reduced rate to become a Power Package member.

Click here to start your Power Package membership.

 

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the premium members only content click here to join.

You will be given immediate access to premium content on the site.

Benefits of Premium Membership include:

  • access to all site content and  newsletter reports
  • acess to all portfolio information and transaction alerts
  • access to all Special Feature, Industry Focus, and Companies in Focus reports
  • email alerts of transactions and any portfolio changes